Two biotechnology companies have closed substantial funding rounds as part of Fierce Biotech’s 2026 fundraising tracker, underscoring sustained investor interest in the life sciences sector despite a broader climate of cautious venture spending. InduPro has assembled $77 million in fresh capital, while Vaderis has closed a $152 million Series B round, according to the tracker’s latest update.
The two raises, disclosed together in Fierce Biotech’s ongoing coverage of 2026 biotech financings, add to a growing list of sizable rounds this year as private investors continue to back companies developing new therapeutic approaches. Neither company’s specific research focus, investor syndicate, or intended use of proceeds was detailed in the disclosure, but the scale of both rounds points to continued confidence among specialist biotech investors in backing companies through multiple stages of development.
InduPro’s $77 million raise adds the company to a cohort of biotech firms securing meaningful early-to-mid-stage funding in 2026, a year that has already seen a steady cadence of rounds tracked by industry publications monitoring the sector’s capital flows. Vaderis’s $152 million Series B is notably larger, reflecting the kind of late-stage capital injection typically reserved for companies that have cleared earlier proof-of-concept milestones and are preparing for more advanced trials or expanded operations.
Series B Signals Shift Toward Later-Stage Bets
Industry observers tracking biotech financing trends have noted that Series B rounds of this size suggest investors remain willing to commit substantial capital once companies have moved beyond seed and Series A validation stages. Vaderis’s closing fits that pattern, representing one of the larger later-stage rounds recorded so far in the 2026 tracker and signaling that specialist life sciences funds are still prepared to deploy significant sums into companies they view as having cleared early scientific and regulatory risk.
Taken together, the InduPro and Vaderis raises illustrate the range of funding activity currently underway in biotech, spanning earlier growth rounds through to more mature Series B financings. Fierce Biotech’s tracker has continued to log such rounds throughout the year, offering a running record of where private capital is flowing within the sector.
Neither transaction carries an explicit Gulf connection, and both appear rooted in the U.S. biotech ecosystem that Fierce Biotech primarily covers. Even so, the rounds are relevant to institutional investors across the UAE and wider GCC who allocate capital to global life sciences funds or co-invest alongside international venture and growth-equity firms. Gulf sovereign wealth funds and family offices have in recent years expanded exposure to biotechnology and healthcare innovation as part of broader efforts to diversify portfolios beyond energy and real estate, often through participation in international funds rather than direct deals.
As the 2026 fundraising cycle continues, further disclosures are expected from Fierce Biotech’s tracker, which has served as a running barometer of biotech capital formation throughout the year. For regional investors monitoring global healthcare and life sciences trends, rounds such as those closed by InduPro and Vaderis offer a window into which stages of the biotech pipeline are currently attracting the deepest pools of private capital, information that can inform decisions on fund allocations or co-investment opportunities tied to the broader international biotech market.
